ClinicalTrialsFinder
RecruitingNot ApplicableNCT07167381

xDRIVE for Florida-based Cancer Patients

xDRIVE Functional Precision Medicine + Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients With Relapsed/ Refractory Cancers

Sponsor

First Ascent Biomedical Inc.

Enrollment

210 participants

Start Date

Nov 1, 2025

Study Type

INTERVENTIONAL

Conditions

CancerLeukaemiaLymphomaSolid Tumor MalignanciesSolid CancersRecurrenceNeoplamsRefractory

Summary

Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).

Eligibility

Plain Language Summary

Simplified for easier understanding

This study (xDRIVE) uses tumor genetic testing and AI to help match Florida cancer patients with the clinical trial or treatment most likely to work for their specific cancer. It is a precision oncology program — rather than a single treatment, it uses your tumor's DNA to personalize recommendations. **You may be eligible if...** - You have cancer that has come back or stopped responding to treatment (recurrent or refractory) - You are any age (children and adults are both eligible) - You have received at least one prior standard treatment - You are healthy enough to undergo cancer therapy (ECOG 0–2 for adults) - You are scheduled for or have recently had a tumor biopsy, removal, or resection - You are willing to provide a blood sample or cheek swab **You may NOT be eligible if...** - You are unable to provide prior treatment information - You are not able to provide a tissue sample for DNA analysis - You are not in sufficient health to receive treatment Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your DoctorCheck Your Eligibility

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTxDRIVE Tumor Profiling

Patients and physicians will receive tumor profiling data via xDRIVE Functional Precision Medicine and Artificial Intelligence analysis. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment.

Locations(2)

First Ascent Biomedical

Miami, Florida, United States

Florida International University

Miami, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07167381

Related Trials

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT0683556910 locations

EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

NCT041414626 locations

Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only

NCT0686770536 locations

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT0662408516 locations

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT0608493675 locations